Last reviewed · How we verify
Placebo matching depemokimab
Depemokimab is a monoclonal antibody that inhibits interleukin-4 receptor alpha (IL-4Rα) to reduce type 2 inflammatory responses.
Depemokimab is a monoclonal antibody that inhibits interleukin-4 receptor alpha (IL-4Rα) to reduce type 2 inflammatory responses. Used for Eosinophilic esophagitis, Eosinophilic gastritis.
At a glance
| Generic name | Placebo matching depemokimab |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | IL-4 receptor antagonist monoclonal antibody |
| Target | IL-4Rα (Interleukin-4 receptor alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy / Respiratory |
| Phase | Phase 3 |
Mechanism of action
Depemokimab blocks IL-4Rα signaling, which is a key driver of type 2 inflammation involving Th2 cells, eosinophils, and IgE production. By inhibiting this pathway, the drug reduces eosinophilic and allergic inflammatory responses. This mechanism is relevant to eosinophilic and allergic diseases where IL-4Rα-mediated signaling plays a central pathogenic role.
Approved indications
- Eosinophilic esophagitis
- Eosinophilic gastritis
Common side effects
- Injection site reactions
- Headache
- Upper respiratory tract infection
Key clinical trials
- eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation (PHASE3)
- Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial (PHASE3)
- Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (PHASE3)
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (PHASE3)
- Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching depemokimab CI brief — competitive landscape report
- Placebo matching depemokimab updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI